PBA
SRRA

Paradigm Biocapital Advisors’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Paradigm Biocapital Advisors’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-801,314
Closed -$44.1M – 33
2022
Q2 		$44.1M Buy
801,314
+30,000
+4% +$1.57M 8.79% 4
2022
Q1 		$24.7M Buy
771,314
+296,369
+62% +$8.5M 6.54% 5
2021
Q4 		$10.3M Buy
+474,945
New +$10.5M 2.95% 14

Other funds holding SRRA

HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Paradigm Biocapital Advisors's SRRA Position: Q3 2022 in Review

Paradigm Biocapital Advisors sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 801,314 shares — an estimated $44.1M sold.

Paradigm Biocapital Advisors first reported a position in SRRA in Q4 2021 and held it in 3 quarters. The position peaked at $44.1M in Q2 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.

  • Paradigm Biocapital Advisors reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 801,314 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $44.1M.
  • Paradigm Biocapital Advisors first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Paradigm Biocapital Advisors's Sierra Oncology, Inc. Common Stock position peaked at $44.1M in Q2 2022.
  • 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.